var data={"title":"Cladribine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cladribine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5912?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cladribine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cladribine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cladribine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cladribine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708674\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Cladribine should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Acute nephrotoxicity has been observed with high doses of cladribine (4 to 9 times the recommended dose for hairy cell leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28104203\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cladribine Injection;</li>\n      <li>Mavenclad</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152320\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Purine Analog);</li>\n      <li>\n        Immunosuppressant Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152286\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>If active infection is present, manage as appropriate prior to cladribine administration. If it is not possible to control infection, consider an alternative agent if possible (Grever 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hairy cell leukemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.14 mg/kg/day over 2 hours for 5 days (Grever 2017) <b>or</b> 0.1 mg/kg/day continuous infusion for 7 days for 1 cycle (Goodman 2003; Saven 1998) <b>or</b> 0.09 mg/kg/day continuous infusion for 7 days for 1 cycle (Cladribine labeling [Fresenius] August 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ (off-label route): 0.1 to 0.14 mg/kg/day for 5 days (Grever 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (newly diagnosed), induction (off-label use):</b> DAC regimen: IV: 5 mg/m<sup>2</sup> over 3 hours on days 1 to 5 (in combination with daunorubicin and cytarabine); a second induction cycle may be administered if needed (Holowiecki 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (relapsed/refractory), induction (off-label use): </b>CLAG or CLAG-M regimen: IV: 5 mg/m<sup>2</sup>/day over 2 hours for 5 days (in combination with cytarabine and filgrastim &plusmn; mitoxantrone); a second induction cycle may be administered if needed (Robak 2000; Wierzbowska 2008; Wrzesie&#324;-Ku&#347; 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma (off-label use):</b> IV: 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 4 weeks for 2 to 6 cycles (Inwards 2008) <b>or</b> 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 4 to 5 weeks for a maximum of 6 cycles (Rummel 1999) <b>or</b> 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 4 weeks for 2 to 6 cycles (in combination with rituximab) (Inwards 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis: Mavenclad [Canadian product; not available in the US]: </b>Oral: 3.5 mg/kg over 2 years, administered as 1.75 mg/kg in each year (divided over 4 to 5 days in each of 2 treatment weeks per year; Usual dose: 10 or 20 mg once daily for 4 to 5 days in weeks 1 and 2 each year for 2 years); refer to manufacturer's labeling for additional dosing details, including dosing tables.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>T-cell large granular lymphocytic leukemia, refractory (off-label use):</b> IV: 0.1 mg/kg/day continuous infusion for 7 days for 2 cycles (Edelman 1997). Additional trials are necessary to further define the role of cladribine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m macroglobulinemia (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.1 mg/kg/day continuous infusion for 7 days every 4 weeks for 2 cycles (Dimopoulos 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 0.1 mg/kg/day for 5 consecutive days every month for 4 cycles (in combination with rituximab) (Laszlo 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152303\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cladribine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cladribine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (off-label use):</b> IV: 8.9 mg/m<sup>2</sup>/day continuous infusion for 5 days for 1 or 2 courses (Krance, 2001) <b>or</b> 9 mg/m<sup>2</sup>/day over 30 minutes for 5 days for 1 course (in combination with cytarabine) (Crews 2002; Rubnitz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Langerhans cell histiocytosis, refractory (off-label use):</b> IV: 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 21 days for up to 6 cycles (Weitzman 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152287\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5527019\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (due to inadequate data); use with caution. The following adjustments have been used (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;60 mL/minute: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5527020\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no dosage adjustments provided in the manufacturer's labeling (due to inadequate data); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (Child-Pugh classes B and C): Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20339799\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer (excluding leukemias): Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152263\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/10 mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152250\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50930332\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Mavenclad: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152266\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Usually administered as a continuous infusion or over 2 hours; infusions over 30 minutes or over 3 hours have also been reported; refer to specific reference for infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ (off-label route): May also be administered SubQ (Grever 2017; Laszlo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]: Administer with water (with or without food); swallow whole immediately after removing from packaging; do not chew or allow to dissolve in mouth. Patients should use dry hands for handling; wash hands thoroughly afterwards. Refer to manufacturer's labeling for additional administration detail.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130932\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).    </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152264\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hairy cell leukemia</b>: Treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis (oral tablet [Canadian product]):</b> Treatment of relapsed-remitting multiple sclerosis (RRMS) to reduce the frequency of exacerbations and to delay the progression of disability in adults who have had inadequate response or are intolerant to one or more other therapies. <b>Note:</b> Not an approved use in the US; dosage form (oral tablet) is not available in the US.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722026\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myeloid leukemia (AML) (adults); Acute myeloid leukemia (AML) (children/adolescents); Langerhans cell histiocytosis (refractory) (children); Mantle cell lymphoma; T-cell large granular lymphocytic leukemia (refractory); Waldenstr&ouml;m macroglobulinemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152326\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cladribine may be confused with clevidipine, clofarabine, cytarabine, fludarabine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leustatin may be confused with lovastatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152257\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (11% to 45%), headache (7% to 22%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (10% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (22% to 28%), decreased appetite (8% to 17%), vomiting (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (grade 4: 70%; recovery by week 5), febrile neutropenia (8% to 47%; severe: 32%), anemia (1% to 37%; recovery by week 8), bone marrow depression (34%; prolonged), thrombocytopenia (grade 4: 12%; recovery by day 12)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (month 1: 28% [serious: 6%]; month 2: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (9% to 19%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Abnormal breath sounds (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (33% to 69%; &ge;100&deg;F: 67%; &ge;104&deg;F: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (2% to 6%), tachycardia (2% to 6%), phlebitis (2%), thrombosis (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (6% to 9%), chills (2% to 9%), malaise (5% to 7%), insomnia (3% to 7%), pain (6%), anxiety (1%), myasthenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis (9%), erythema (6%), pruritus (2% to 6%), hyperhidrosis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (7% to 10%), constipation (4% to 9%), abdominal pain (4% to 6%), flatulence (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Purpura (10%), petechia (2% to 8%), bruise (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (6% to 9%), myalgia (6% to 7%), arthralgia (3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (7% to 10%), dyspnea (5% to 7%), epistaxis (5%), rales (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Aplastic anemia, bacteremia, cellulitis, cerebrovascular accident, confusion, conjunctivitis, decreased CD-4 cell count (nadir: 4 to 6 months), eosinophilia (hypereosinophilia or persistent), hemolytic anemia, hypersensitivity reaction, impaired consciousness, increased serum bilirubin, increased serum transaminases, lower extremity weakness, myelodysplastic syndrome, opportunistic infection (cytomegalovirus disease, fungal infection, herpes virus infection, listeriosis, <i>Pneumocystis jirovecii</i>), pancytopenia (prolonged), paresis (at high doses; paraparesis/quadriparesis), pneumonia, polyneuropathy (with high doses), progressive multifocal leukoencephalopathy, pulmonary infiltrates (interstitial), reactivated tuberculosis, renal failure, renal insufficiency (with high doses), septic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis, tumor lysis syndrome, urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152269\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cladribine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]: Hypersensitivity to cladribine or any component of the formulation; patients at increased risk of opportunistic infections (including those immunocompromised due to therapy [immunosuppressive or immunomodulating, antineoplastic or myelosuppressive therapies; total lymphoid irradiation; bone marrow transplantation] or disease [immunodeficiency syndrome]); latent or active infections (including active chronic bacterial, fungal or viral infections [eg, hepatitis, tuberculosis]); history of progressive multifocal leukoencephalopathy; active malignancy; moderate or severe renal impairment (CrCL &lt;60 mL/minute); pregnancy; breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152254\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Dose-dependent myelosuppression (neutropenia, anemia, and thrombocytopenia) is common and generally reversible.</b> Use with caution in patients with preexisting hematologic or immunologic abnormalities. Monitor blood counts, especially during the first 4 to 8 weeks after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fever: Treatment is associated with fever (&ge;100&deg;F), with or without neutropenia, and is observed more commonly in the first month of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Infections (bacterial, viral, and fungal) were reported more commonly in the first month after treatment (generally mild or moderate in severity, although serious infections including sepsis have been reported); the incidence is reduced in the second month. Due to neutropenia and T-cell depletion, risk versus benefit of treatment should be evaluated in patients with active infections. If active infection is present, manage appropriately prior to administering cladribine (Grever 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: Serious, dose-related neurologic toxicity (including irreversible paraparesis and quadriparesis) has been reported with continuous infusions of higher doses (4 to 9 times the approved dose); may also occur at approved doses (rare).</b> Neurotoxicity may be delayed and may present as progressive, irreversible motor weakness of the upper and/or lower extremities; diagnostics with electromyography and nerve conduction studies were consistent with demyelinating disease. Neurotoxicity after high-dose administration was first noted 35 to 84 days after therapy initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: <b>[US Boxed Warning]: Acute nephrotoxicity (eg, acidosis, anuria, increased serum creatinine), possibly requiring dialysis, has been reported with high doses (4 to 9 times the approved dose), particularly when administered with other nephrotoxic agents.</b> Per the manufacturer, nephrotoxicity has not occurred when used at the dose approved for hairy cell leukemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: With high tumor burden, tumor lysis syndrome and subsequent hyperuricemia may occur (rare); consider antihyperuricemics and hydrate accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Weekly (7-day) infusion preparation recommends further dilution with bacteriostatic normal saline which contains benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral tablet [Canadian product]: Multiple sclerosis: Use is contraindicated in patients with active or latent tuberculosis. Complete immunizations at least 6 weeks prior to treatment initiation. Evaluate hepatitis B and C status prior to treatment. Assess varicella zoster virus (VZV) antibody status prior to treatment; if no confirmed history of chicken pox or vaccination and VZV antibody is negative, vaccination is recommended (delay cladribine for 6 weeks after vaccination). Only initiate treatment if lymphocyte counts are normal, Obtain a baseline MRI if patient has previously received MS therapy associated with progressive multifocal leukoencephalopathy (PML); do not initiate or re-initiate therapy until PML has been excluded. May be associated with an increased risk of malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Administration of live vaccines is not recommended during treatment with cladribine (may increase the risk of infection due to immunosuppression).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299054\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219339\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9272&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152259\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3016299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of reproductive potential should use highly effective contraception during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oral tablet [Canadian product]: Use is contraindicated in pregnancy. Exclude pregnancy prior to treatment. Females of reproductive potential and males with female partners of reproductive potential should use effective contraception during treatment and for 6 months after the final cladribine dose. Women who become pregnant during therapy should discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3016301\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if cladribine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the decision to discontinue cladribine or to discontinue breastfeeding should take into account the importance of treatment to the mother.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152261\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: CBC with differential (particularly during the first 4 to 8 weeks post-treatment), renal and hepatic function; bone marrow biopsy (after CBC has normalized, to confirm treatment response); monitor for fever; monitor for signs/symptoms of neurotoxicity and infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]: CBC including lymphocyte count (within 6 months prior to treatment initiation or after discontinuation of prior therapy; assess lymphocyte count prior to initiation in year 1 and year 2 and periodically in between and after treatment); evaluate hepatitis B (HBV) and hepatitis C (HCV) status (prior to treatment); evaluate varicella zoster virus VZV antibody status (prior to treatment); pregnancy test (prior to treatment in females of reproductive potential); MRI (at baseline if received prior MS therapy associated with PML).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152253\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cladribine is a purine nucleoside analogue; it is a prodrug which is activated via phosphorylation by deoxycytidine kinase to a 5'-triphosphate derivative (2-CaAMP). This active form incorporates into DNA to result in the breakage of DNA strand and shutdown of DNA synthesis and repair. This also results in a depletion of nicotinamide adenine dinucleotide and adenosine triphosphate (ATP). Cladribine is cell-cycle nonspecific.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152268\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 8 months to 18 years: 12.7 &plusmn; 8.5 L/kg; penetrates CSF (CSF concentrations are ~18% of plasma concentration) (Kearns 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~9 L/kg; penetrates CSF (CSF concentrations are ~25% of plasma concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 8 months to 18 years: 19.7 &plusmn; 3.4 hours (Kearns 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: After a 2-hour infusion (with normal renal function): 5.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Absorption: Rapid; delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bioavailability: ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Half-life elimination: ~24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Time to peak: 30 to 90 minutes (fasting); 1 to 3 hours (with high-fat meal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323071\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cladribine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $420.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038562\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ai Bo Ding (CN);</li>\n      <li>Biodribin (PL);</li>\n      <li>Cladrim (IN);</li>\n      <li>Intocel (AR);</li>\n      <li>Kitak (RO);</li>\n      <li>Leustat (AR, GB, IE);</li>\n      <li>Leustatin (AT, AU, BE, BG, BR, CH, CR, DO, ES, FI, GR, GT, HK, HN, IT, KR, LU, NI, NL, NZ, PA, PH, PT, SE, SG, SV, TW, UY, VE);</li>\n      <li>Leustatine (FR);</li>\n      <li>Litak (AE, AT, AU, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IL, IT, JO, LB, LT, LV, MT, NL, NO, PL, PT, RU, SE, SI, SK, TR, TW);</li>\n      <li>Mavenclad (CZ);</li>\n      <li>Plane (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernard F, Thomas C, Bertrand Y, et al, &ldquo;Multi-Centre Pilot Study of 2-Chlorodeoxyadenosine and Cytosine Arabinoside Combined Chemotherapy in Refractory Langerhans Cell Histiocytosis With Haematological Dysfunction,&rdquo; <i>Eur J Cancer</i>, 2005, 41(17):2682-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/16291085/pubmed\" target=\"_blank\" id=\"16291085\">16291085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cladribine injection [prescribing information]. Lake Surich, IL: Fresenius Kabi; August 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cladribine injection [product monograph]. Richmond Hill, Ontario, Canada: Fresenius Kabi Canada Ltd; June 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12377965\"></a>Crews KR, Gandhi V, Srivastava DK, et al, &ldquo;Interim Comparison of a Continuous Infusion versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia,&rdquo; <i>J Clin Oncol</i>, 2002, 20(20):4217-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/12377965/pubmed\" target=\"_blank\" id=\"12377965\">12377965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7989946\"></a>Dimopoulos MA, Kantarjian H, Weber D, et al, &ldquo;Primary Therapy of Waldenstr&ouml;m's Macroglobulinemia With 2-Chlorodeoxyadenosine,&rdquo; <i>J Clin Oncol</i>, 1994, 12(12):2694-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/7989946/pubmed\" target=\"_blank\" id=\"7989946\">7989946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9092691\"></a>Edelman MJ, O&rsquo;Donnell RT, Meadows I. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. <i>Am J Hematol.</i> 1997;54(4):329-331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9092691/pubmed\" target=\"_blank\" id=\"9092691\">9092691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodman GR, Burian C, Koziol JA., et al, &ldquo;Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine,&rdquo; <i>J Clin Oncol</i>, 2003, 21(5):891-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/12610190/pubmed\" target=\"_blank\" id=\"12610190\">12610190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i>. 2017;129(5):553-560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/27903528/pubmed\" target=\"_blank\" id=\"27903528\">27903528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22508825\"></a>Holowiecki J, Grosicki S, Giebel S, et al, &quot;Cladribine, but not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study,&quot; <i>J Clin Oncol</i>, 2012, 30(20):2441-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/22508825/pubmed\" target=\"_blank\" id=\"22508825\">22508825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18470909\"></a>Inwards DJ, Fishkin PA, Hillman DW, et al, &ldquo;Long-Term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group,&rdquo; <i>Cancer</i>, 2008, 113(1):108-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/18470909/pubmed\" target=\"_blank\" id=\"18470909\">18470909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns CM, Biakley RL, Santane VM, et al, Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. <i>Cancer Research</i>. 1994;54:1235-1239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/7906999/pubmed\" target=\"_blank\" id=\"7906999\">7906999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11387351\"></a>Krance RA, Hurwitz CA, Head DR, et al, &ldquo;Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases,&rdquo; <i>J Clin Oncol</i>, 2001, 19(11):2804-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11387351/pubmed\" target=\"_blank\" id=\"11387351\">11387351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20368573\"></a>Laszlo D, Andreola G, Rigacci L, et al, &ldquo;Rituximab and Subcutaneous 2-Chloro-2'-Deoxyadenosine Combination Treatment for Patients With Waldenstr&ouml;m Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study,&rdquo; <i>J Clin Oncol</i>, 2010, 28(13):2233-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20368573/pubmed\" target=\"_blank\" id=\"20368573\">20368573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leustatin (cladribine) [prescribing information]. Raritan, NJ: Centocor Ortho Biotech Products; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mavenclad (cladribine) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ravandi F, O'Brien S, Jorgensen J, et al, &quot;Phase 2 Study of Cladribine Followed by Rituximab in Patients With Hairy Cell Leukemia,&quot; <i>Blood</i>, 2011, 118(14):3818-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/21821712/pubmed\" target=\"_blank\" id=\"21821712\">21821712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robak T, &ldquo;Cladribine in the Treatment of Chronic Lymphocytic Leukemia,&rdquo; <i>Leuk Lymphoma</i>, 2001, 40(5-6):551-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11426528/pubmed\" target=\"_blank\" id=\"11426528\">11426528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robak T, Jamroziak K, Gora-Tybor J, et al, &quot;Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide as First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study),&quot; <i>J Clin Oncol</i>, 2010, 28(11):1863-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20212251/pubmed\" target=\"_blank\" id=\"20212251\">20212251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10975390\"></a>Robak T, Wrzesie&#324;-Ku&#347; A, Lech-Mara&#324;da E, et al, &ldquo;Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia,&rdquo; <i>Leuk Lymphoma</i>, 2000, 39(1-2):121-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/10975390/pubmed\" target=\"_blank\" id=\"10975390\">10975390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19242495\"></a>Rubnitz JE, Crews KR, Pounds S, et al, &ldquo;Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St Jude AML97 Trial,&rdquo; <i>Leukemia</i>, 2009, 23(8):1410-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/19242495/pubmed\" target=\"_blank\" id=\"19242495\">19242495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10076731\"></a>Rummel MJ, Chow KU, J&auml;ger E, &ldquo;Treatment of Mantle Cell Lymphomas With Intermittent Two-Hour Infusion of Cladribine as First-Line Therapy or in First Relapse,&rdquo; <i>Ann Oncol</i>, 1999, 10(1):115-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/10076731/pubmed\" target=\"_blank\" id=\"10076731\">10076731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saven A, Burian C, Koziol JA, et al, &ldquo;Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment,&rdquo; <i>Blood</i>, 1998, 92(6):1918-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9731048/pubmed\" target=\"_blank\" id=\"9731048\">9731048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sigal DS, Miller HJ, Schram ED, et al, &ldquo;Beyond Hairy Cell: The Activity of Cladribine in Other Hematologic Malignancies,&rdquo; <i>Blood</i>, 2010, 116(16):2884-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20634380/pubmed\" target=\"_blank\" id=\"20634380\">20634380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sigal DS, Sharpe R, Burian C, et al, &ldquo;Very Long-Term Eradication of Minimal Residual Disease in Patients With Hairy Cell Leukemia After a Single Course of Cladribine,&rdquo; <i>Blood</i>, 2010, 115(10):1893-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20056789/pubmed\" target=\"_blank\" id=\"20056789\">20056789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stine KC, Saylors RL, Saccente S, et al, &ldquo;Efficacy of Continuous Infusion 2-CDA (Cladribine) in Pediatric Patients With Langerhans Cell Histiocytosis,&rdquo; <i>Pediatr Blood Cancer</i>, 2004, 43(1):81-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/15170896/pubmed\" target=\"_blank\" id=\"15170896\">15170896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19731321\"></a>Weitzman S, Braier J, Donadieu J, et al, &ldquo;2'-Chlorodeoxyadenosine (2-CdA) as Salvage Therapy for Langerhans Cell Histiocytosis (LCH). Results of the LCH-S-98 Protocol of the Histiocyte Society,&rdquo; <i>Pediatr Blood Cancer</i>, 2009, 53(7):1271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/19731321/pubmed\" target=\"_blank\" id=\"19731321\">19731321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18076637\"></a>Wierzbowska A, Robak T, Pluta A, et al, &ldquo;Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group,&rdquo; <i>Eur J Haematol</i>, 2008, 80(2):115-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/18076637/pubmed\" target=\"_blank\" id=\"18076637\">18076637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12930315\"></a>Wrzesie&#324;-Ku&#347; A, Robak T, Lech-Mara&#324;da E, et al, &ldquo;A Multicenter, Open, Non-Comparative Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia &ndash; a Report of the Polish Adult Leukemia Group (PALG),&rdquo; <i>Eur J Haematol</i>, 2003, 71(3):155&ndash;62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/12930315/pubmed\" target=\"_blank\" id=\"12930315\">12930315</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9272 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708674\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28104203\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F152320\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F152286\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F152303\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F152287\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5527019\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5527020\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20339799\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F152263\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F152250\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50930332\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F152266\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130932\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F152264\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722026\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F152326\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F152257\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152269\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152254\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299054\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219339\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F152259\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3016299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3016301\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F152261\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152253\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F152268\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323071\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038562\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9272|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cladribine-patient-drug-information\" class=\"drug drug_patient\">Cladribine: Patient drug information</a></li><li><a href=\"topic.htm?path=cladribine-pediatric-drug-information\" class=\"drug drug_pediatric\">Cladribine: Pediatric drug information</a></li></ul></div></div>","javascript":null}